increasing sales of selective serotonin reuptake inhibitors are closely related to increasing number...
TRANSCRIPT
Increasing sales of selective serotonin reuptake inhibitors are closely related to
increasing number of products on the market Margrethe Nielsen
PhD student
The Nordic Cochrane CentreConflicts of interests: None
Sales of all psychoactive drugs in DenmarkDDD: defined daily doses per 1,000 inhabitants
0
20
40
60
80
100
120
140
160
year
DD
D
antipsychotics, anxiolytics andhypnotics
antidepressants, psychostimulants,antidementia
total
Influence of benzos and neurotransmitter reuptake inhibitors on total usage
0
20
40
60
80
100
120
140
160
year
DD
D all psychoactive drugs - total
benzos and neurotransmitter reuptake inhibitors
The total sales of benzodiazepines and benzodiazepine-like drugs and neurotransmitter
reuptake inhibitors
0
20
40
60
80
100
120
year
DD
D
Total benzodiazepines
Total neurotransmitter reuptakeinhibitors
Possible explanations
Sales of all psychoactive drugs in Denmark – changes in disease classification systems
0
20
40
60
80
100
120
140
160
year
DD
D
antipsychotics, anxiolytics andhypnotics
antidepressants, psychostimulants,antidementia
total
Symptoms
and increasing
number of diagnoses
Increasing number of symptoms for the diagnosis of depression
implementing and harmonising
SSRI DDD, number of products and indications
0
10
20
30
40
50
60
1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005/ 06
2007 2008
year
nu
mb
er o
f D
DD
an
d n
um
ber
of
pro
du
cts
number of indications
Number of SSRI products
SSRI DDD
Benzo DDD, number of indications and products
0
20
40
60
80
100
120
year
indications
number of benzodiazepine product
benzo DDD
Recommendation of screening from referenceprogram from the National Board of Health
• ”In the literature there is conflicting information about the efficacy of systematic screening for depression, in order to ensure that more people are treated. A newer Cochrane review is thus showing minimal influence of systematic screening on the degree of diagnostics, treatment and outcome. There is on the other hand a generel agreement that screening for depression in risk groups can improve outcome, for example for patients with stroke or heart disease.”(my translation)(IIb)
The Commission’s proposal on information to patients (1)
• Enable citizens to get high-quality informa-tion about prescription only-medicines
• Pharmaceutical companies should disseminate informa-tion about drugs
• Certain information in a new presentation
The Commission’s proposal on information to patients (2)
• Allowing the pharma-ceutical industry to promote their products to the public
• No clear distinction between advertising and information
• Comparisons between medicinal products are not allowed
